Donor mobilized PBSC infusion + G-CSF + Total Body Irradiation (TBI) (Plan 1) + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 Jul 2018: Trial registered, NCT03579875
  2. 13 Nov 2018: Trial started, NCT03579875

The trials

NCT03579875: Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

State
Under way
Phase
Phase 2
People
48 planned
Started
13 Nov 2018
Primary completion
1 Jan 2027
Arms
Treatment Plan 1: TBI 300 , CY, FLU, MP, Rituximab in patients with Fanconi Anemia
Results
None posted
  1. 9 Jul 2018: Trial registered
  2. 13 Nov 2018: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.